 |
  
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Evaluation of the Antiviral Nucleoside Lobucavir Against Woodchuck Hepatitis Virus (WHV) in Chronically Infected WoodchucksApril 11, 1997
I. Medina, et al
Lobucavir has activity against human hepatitis B virus (HBV) (EC50 = 2.5 uM in HepG2.2.15 cells). This poster presented the efficacy of Lobucavir in woodchuck model. Animals chronically infected with hepatitis B (WHV) were dosed orally with Lobucavir (10 or 20 mg/kg daily). Serum levels of WHV DNA were generally reduced to below limit of detection (about 2 log reduction) after 1-2 weeks of treatment and returned to base-line within 1-2 weeks after therapy. Lower doses were less effective. Although Lobucavir was effective in this model, its efficacy and potency is markedly less than that of BMS-200475 (see #32 in this report). However, BMS-200475 is only starting phase I clinical trials whereas a Lobucavir trial in hepatitis patients is already ongoing.  This article was provided by The Body PRO. It is a part of the publication The 10th Annual International Society For Antiviral Research Conference. |
 |
Email
Print-Friendly
Glossary
The Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
